Axsome Therapeutics
AXSM | NASDAQ
$137.01
-$4.68 (-3.30%)
At close: Nov 16, 2026, 4:00 PM ET
$137.50
+$0.49 (+0.36%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Axsome Therapeutics Company Profile
Company profile explainedCompany Profile
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.
Key Executives
| Name | Position |
|---|---|
| Herriot Tabuteau | Founder, Chairman, Chief Executive Officer & President |
| Mark L. Jacobson | Chief Operating Officer |
| Nick Pizzie | Chief Financial Officer |
| Ari Maizel | Chief Commercial Officer |
| Darren Opland | Director of Corporate Communications |
| Hunter Murdock | General Counsel & Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 03, 2026 | 4 | Filing |
| Aug 10, 2026 | 10-Q | Quarterly Report |
| Aug 10, 2026 | 8-K | Current Report |
| Aug 07, 2026 | 4 | Filing |
| Jul 27, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Jul 15, 2026 | 8-K | Current Report |
| Jul 01, 2026 | 4 | Filing |
| Jun 11, 2026 | 4 | Filing |
| Jun 10, 2026 | 4 | Filing |
| Jun 10, 2026 | 4 | Filing |
Axsome Therapeutics
| Country | United States |
| IPO Date | Nov 19, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1,346 |
| CEO | Herriot Tabuteau |
Contact Details
One World Trade Center New York City,
New York 10007 United States
Stock Details
| Ticker Symbol | AXSM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001579428 |
| CUSIP Number | 05464T104 |
| ISIN Number | US05464T1043 |
| SIC Code | 2834 |
Recent News
- 18 hours ago / marketbeat.comAxsome Therapeutics Sees AUVELITY Prescription Surge After Alzheimer's Agitation Launch
- 18 hours ago / seekingalpha.comAxsome Therapeutics, Inc. (AXSM) Presents at UBS Global Biopharma Conference 2026 Transcript
- 7 days ago / marketbeat.comAxsome Therapeutics Tops $1 Billion Revenue Run Rate as AUVELITY Sales Surge
- 8 days ago / seekingalpha.comAxsome Therapeutics, Inc. (AXSM) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript
- 12 days ago / fool.comAxsome Therapeutics vs. BioNTech: Which Healthcare Stock Is a Better Buy for 2027?
- 13 days ago / fool.comAxsome: 3 Key Takeaways for Long-Term Investors
- 14 days ago / globenewswire.comAxsome Therapeutics to Participate in Upcoming Investor Conferences
- 14 days ago / seekingalpha.comAxsome Therapeutics: Sentiment Meets Reality After Q3 (Rating Upgrade)
- 15 days ago / seekingalpha.comAxsome Therapeutics, Inc. (AXSM) Q3 2026 Earnings Call Transcript
- 15 days ago / marketbeat.comWhat Axsome Therapeutics (AXSM) Said on Its Q3 Earnings Call
Add to Watchlist
Select watchlists to add or remove AXSM